Daniel Judge, MD, on Translational Gene Therapy for Cardiac Disorders
Genetics is the future of heart failure and cardiomyopathy treatment, Judge told CGTLive in an interview.
We’re realizing more and more that people who have unexplained weakness or thickness in their heart, cardiomyopathy, have that on a genetic basis. It may not be available when you look at their family, you may not see others with the same condition, but when you look at a genetic level, more and more we’re identifying specific genes that are altered.
Daniel Judge, MD, a professor of medicine in cardiology at the Medical University of South Carolina, believes that the application of exciting translational science in cardiovascular diseases will lead to new, groundbreaking genetic therapies for people with heart failure and cardiomyopathy.
Judge is leading a large-scale
In an interview with CGTLive, Judge discusses some of the translational science that has him especially excited, including applications of gene editing and silencing for cardiology-related disorders.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025